Ibrance and Enteritis infectious - a phase IV clinical study of FDA data

Summary:

Enteritis infectious is reported as a side effect among people who take Ibrance (palbociclib), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Pantoprazole, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Enteritis infectious when taking Ibrance. It is created by eHealthMe based on reports of 104,340 people who have side effects when taking Ibrance from the FDA, and is updated regularly.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

What is Enteritis infectious?

Enteritis infectious (infection with feline parvovirus (fpv), also known as feline panleucopenia virus) is found to be associated with 361 drugs and 416 conditions by eHealthMe. Check the latest studies of Enteritis infectious.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

104,340 people reported to have side effects when taking Ibrance.
Among them, 33 people (0.03%) have Enteritis infectious.

Could Ibrance cause Enteritis infectious?

Among these 33 people:

How long have people been on Ibrance when they have Enteritis infectious? *

What is the gender of people who have Enteritis infectious when taking Ibrance? *

female: 96.97 %
male: 3.03 %

What is the age of people who have Enteritis infectious when taking Ibrance? *

What are other drugs people take besides Ibrance? *

Ativan: 9 people, 27.27%
Botox: 9 people, 27.27%
Pantoprazole: 9 people, 27.27%
Faslodex: 6 people, 18.18%
Metformin: 5 people, 15.15%
Meclizine Hydrochloride: 4 people, 12.12%
Compazine: 4 people, 12.12%
Lisinopril: 4 people, 12.12%
Magnesium: 4 people, 12.12%
Metoprolol Tartrate: 4 people, 12.12%

What are other side effects people have besides Enteritis infectious? *

Abdominal Discomfort: 15 people, 45.45%
Back Pain: 15 people, 45.45%
Neoplasm Progression (growth of tumour): 14 people, 42.42%
White Blood Cell Count Decreased: 14 people, 42.42%
Nosebleed (bleeding from nose): 13 people, 39.39%
Diarrhea: 12 people, 36.36%
Pain In Extremity: 12 people, 36.36%
Fatigue (feeling of tiredness): 11 people, 33.33%
Malaise (a feeling of general discomfort or uneasiness): 10 people, 30.30%
Memory Loss: 10 people, 30.30%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 16 people, 48.48%
Breast Cancer Female: 11 people, 33.33%
Stress And Anxiety: 9 people, 27.27%
Migraine (headache): 9 people, 27.27%
Hyperchlorhydria (gastric acid levels are higher in stomach): 9 people, 27.27%
High Blood Cholesterol: 2 people, 6.06%
Cardiac Disorder: 2 people, 6.06%
Seasonal Allergy (allergic condition due to certain season): 1 person, 3.03%
Neoplasm Malignant (cancer tumour): 1 person, 3.03%
Liposarcoma (a cancer tumour that arises in fat cells in deep soft tissue): 1 person, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrance and have Enteritis infectious?

- Check whether Enteritis infectious is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ibrance:

Ibrance (104,434 reports)

Browse all side effects of Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Enteritis infectious:

Enteritis infectious (361 drugs)

Browse all the conditions that are associated with Enteritis infectious:

Enteritis infectious (416 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on palbociclib (the active ingredients of Ibrance) and Ibrance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.